Boston Scientific Corporation · NYSE:BSX
Boston Scientific — SPAC Merger (December 2005)
10 slides from Boston Scientific's SPAC merger presentation, Dec 5, 2005
Slide 1: Creating the World's Leading Cardiovascular Device Company
Boston Scientific Delivering what's next.’ Creating the World’s Leading Cardiovascular Device Company Accelerating Diversification and Growth December 5, 2005
Slide 2: Forward-Looking Statements
Seerato tp predict and are beyond the contol of Boston 7 ee. referenced in Boston Scientife's flings with the Secunties and Exchange Commission competition, economic conditions, such af interest rate and currency exchange rale fuctuat technological advances and patents attained by compatitors, chall
Slide 3: Additional Information and Where to Find It
Seeantio fen available, which would contain important inf prospectus/proxy statement would be, and oth Boston Scienblic by directing a request to Boston Scien Massachusetts 01760-1537, attention: Milan Kofol, Investor Relation: Boston Scientific is not currently engaged in a solicitation of proxies
Slide 4: Powerful Strategic Rationale
Powerful Strategic Rati Scientific Industry Leadership Acquiring a leading franchise in Enhancing CRM business Diversification & Coun Drives long-term top-line and bottom-line growth = Adds second drug eluting stent program = Steady, diversified cash flow. 2006 EBITDA of greater than Solid Financial
Slide 5: Key businesses of Boston Scientific and Guidant
* Key businesses: * Drug Eluting Stents * Other Cardiovascular * Endosurgery * Neuromodulation = Established industry leader = #1 in DES (55% U.S. share). * 90% of cardiovascular sales from #1 Positioned products: = 75% of other sales from #4 positioned products Boston, Scienufic = Key businesses: *
Slide 6: Boston Scientific
Boston, Scientific
Slide 7: Creating The World's Leading Cardiovascular Device Company
Boston, Creating The World’ diovascular Scentfic Device = Merges two innovative leadei = Leverages strong financial capability to CRM opportunity and complementary DES = Strategic and financial diversification = Multiple growth engines in attractive segments -CRM, neuromodulation, interventional vas
Slide 8: Strength of the BSC Proposal
Boston, Strength of the BSC Proposal: Scienufic pletion Committed financing Divestiture plan = BSC is prepared to divest the Guidant vascular intervention and endovascular businesses while retaining shared rights to Guidant's drug eluting stent program, which it expects will address any competition
Slide 9: Summary
Summary a = The combination creates the world’s leading cardiovascular device company = Powerful strategic and financial rationale = Strength of the BSC Proposal Boston, Scientific
Slide 10: Searchable text section of graphics shown above
Searchable text section of graphics shown above [LO GO] Delivering what’s next. TM Creating the World’s Leading Cardiovascular Device Company Accelerating Diversification and Growth December 5, 2005 [L OGO] Safe Harbor: Forward-Looking Statements This presentation contains “forward-looking statement